Abstract
Genome wide RNA expression profiling has yielded tumor subtypes with strong predictive or prognostic value for a wide variety of cancers. Recently, for breast cancer two RNA expression classifiers have been adopted by the WHO and approved by the FDA. Also on basis of DNA copy number profiles tumor subtypes with different prognosis have been described, but have not yet led to clinical implementation. The genomic revolution caused by next generation sequencing of DNA samples presents additional mutation, balanced translocations, SNPs and copy neutral loss of heterozygosity data simultaneously. We foresee a further boost of the potential of DNA profiling in the clinic when these multidimensional DNA factors will be implemented. Here we evaluate the current stratification power with DNA copy numbers. In a training and validation approach using data of 400 published breast cancer samples, we show that a DNA copy number classifier accurately classifies RNA expression subtypes. We consider this an important step forward for clinical implementation of genomic subtyping using DNA and discuss the extra dimensions upcoming techniques will bring to the DNA palette.
Introduction
Personalized treatment is dependent on biomarkers or molecular profiles with strong prognostic or predictive value. Classically morphological features are used in the pathology laboratory, but metabolites, proteins, DNA, RNA, non-coding RNA, epigenetic features could be a valuable contribution. Whether used separately or in combination, ac ucuracy, reproducibility and robustness are the most important characteristics to warrant clinical implementation (1) . If high-throughput and genome-wide techniques yield subtypes with strong predictive or prognostic value, faster, less invasive and more cost effective procedures, such as RT-PCR, MLPA, immuno histochemistry, or (molecular) imaging may be implemented in the clinic. Of all genome-wide high throughput techniques gene expression profiles have the strongest prognostic value in a wide variety of malignancies; i.e. leukemias, bladder-, breast-, oesophageal-, non-small-celllung-and head and neck cancer (2) . Two breast cancer expression signatures, DNA copy number aberrations to define tumor subtypes with different prognosis have also been described (5) (6) (7) (8) . Specific amplifications and gene fusions such as BCR-ABL, EGFR, NRAS and ErbB2 can be decisive predictive factors (9) . DNA copy number profiles detected by array CGH however have not yet implemented in the clinic. For breast cancer, the prognostic value of the current DNA copy number profiles has been less pronounced and less tightly related to clinico-pathological classifiers such as oestrogen receptor status or ErbB2 expression (5;6). A significant proportion of RNA expression can be explained in terms of underlying DNA copy number aberrations (10 Aim of this perspective is to evaluate the potentials of molecular subtyping using DNA.
We chose for ductal invasive breast cancer as a test case, which is the most well investigated and profiled solid tumor in this respect. We used a data collection of nearly 400 publicly available breast cancer samples, obtained from 4 breast cancer studies where both DNA copy number (array CGH) as well as RNA expression arrays were performed (5;16-18). Here we assess the power of only DNA data and assess if individual patients can be assigned to a subclass. Using a training and validation approach we build a DNA classifier, which accuracy mimics the strong prognostic expression subtypes. This exercise illustrates the potential of DNA as a subtype classifier. By next generation sequencing, mutation data, balanced translocations, SNPs and copy neutral loss of heterozygosity can be simultaneously obtained from DNA (7;19) . We foresee a further boost of the potential of DNA profiling when these multidimensional factors will be implemented. (Table 1) . We adopted the expression subtypes that were all previously determined by each institutions expression array platforms, clustering algorithms and settings. The majority of samples were characterized as the luminal A expression subtype in all 4 datasets (mean 41%, range 36-53%). The basal subtype was the second largest group (mean 20%, range 14-28%). The remaining samples were equally distributed over the ErbB2 (mean 15%, range 12-23%) and luminal B subtypes (mean 14%, range 12-18%) ( To make the 4 different datasets comparable, probes of the respective platforms, i.e.
BACs and oligonucleotides, were remapped to the human genome assembly release 19, NCBI 37 (14). Subsequently, direct combination of data from the different cohorts was performed in a straight forward manner by determining the actual DNA copy number data per array sample (13) . Frequencies of segmented and called DNA copy numbers were then calculated and plotted per segment and subtype for the cumulative set ( Figure   1 ) and for each of 4 separate patient cohorts (Supplementary Figure 1) . DNA frequency plots per RNA expression subtype showed very similar results for the 4 datasets separately, despite demographic and technical differences as well as differences in expression subtype assignments. We therefore conclude that subtyping on basis of DNA copy number aberrations is highly correlated with RNA expression subtypes, validating the findings of Bergamaschi et al. (17) .
A DNA copy number classifier can predict expression subtypes of high prognostic value with high accuracy.
To built a subtype classifier based on DNA copy numbers we combined the first 3 datasets published (5;17;18). The essence is that for each closest corresponding chromosomal location on the "Cambridge" CGH platform the segmented DNA copy number level of the Stanford and UCSF dataset were taken by making use of a gene expression integration R-package called intCNGEan (25) . The collective training set of 296 breast cancer samples (Table 1) 
representative vector of DNA copy aberration distributions for all selected features. The DNA copy number profile of a sample from the Paris data set is compared to the representative vectors of all subgroups, i.e., the distance between the two is calculated.
Subsequently, the sample is assigned to the label of the subgroup with the smallest distance between its representative vector and the DNA copy number profile of the sample. In this way all samples from the Paris dataset (16) The classifier performed with an accuracy of ~70-90% on the samples of the Paris validation set (Table 2 ). This level of accuracy for subtype prediction is high, particularly given that expression subtypes are a weak end point given the demographic and technical differences in addition to the variations in expression subtype assignment by the different research groups (4). Strikingly, the prediction for the luminal B subtype with strong prognostic value is the most accurate, (91%), whereas the distinction between luminal A and B is the most challenging by RNA expression profiling (21;22). The predicted accuracy was however the lowest for the luminal A subtype (73%), which might be attributable to the less distinct DNA copy number aberrations (Figure 1) .
Overall, the exercise with this breast cancer dataset and copy number data shows a strong potential of DNA for subtyping in the clinic. Nevertheless, the unsupervised hierarchical clustering of DNA copy numbers do not yet yield the same strong prognostic value (5;6). This discrepancy may be due to the quality of the algorithms or the (dimensionality) of the array CGH data (13) . Profiling based on chromosomal DNA copy number aberrations alone has specified cancer subtypes with different prognosis. Here we show that even prediction analysis of prognosis using a copy number based classifier is a promising alternative for the clinic. It is important to re-evaluate the current short-comings of DNA copy number based subtyping in terms of prognosis and prediction. For clustering and subtype annotation the amount of variables measured is important (26) . The actual copy number data of the four different studies used in this exercise is of reasonable high resolution, but does not detect focal aberrations as described by recent studies using the latest array CGH 
the breast cancer studies described above (14; 19;27) . Also the prepossessing algorithms are being customized to the discrete nature of chromosomal copy number data (13) . In fact, reanalysis of one breast cancer data set using a DNA copy number dedicated pre-processing and unsupervised clustering algorithm yielded subtypes with higher prognostic value (6;31). These developments highlight the potential of DNA profiling for the clinic in the near future. Either tumors will be classified based on chromosomal copy numbers alone or in combination with balanced translocation and mutation data (7) . The presented exercise illustrates the added value of chromosomal DNA profiling in addition to established and powerful clinico-pathological classifiers such as ER, PR, ErbB2 for breast cancer. Ultimately, profiles need to be implemented in accordance to the REMARK guidelines (1).
For many ongoing studies such as the ATLAS project, as well as clinical trials such as MINDACT, TransBIG and I-SPY, biomaterials are collected and profiling is planned for both RNA expression and DNA aberrations (mutation, translocation, copy number) (32) .
In addition, DNA methylation and non-coding RNAs will be studied. Particularly, the microRNA class of non-coding RNAs are promising in that perspective, since their small size makes them a well preserved entity in FFPE samples and could allow for yet an alternative stratification marker molecule to be applied in the clinic. The jury will be out whether "to DNA or not to DNA?" in daily clinic practice, but we predict a boost for DNA profiling in the near future. 
